## Edgar Filing: Xenon Pharmaceuticals Inc. - Form 4

Xenon Pharmaceuticals Inc.					
Form 4					
March 11, 2016				OMB APP	ROVAL
	E COMMISSION	OMB Number:	3235-0287		
if no longer				Expires:	January 31, 2005 grade
Section 16. Form 4 or Form 5 Filed pure	SECU suant to Section 16(a) of a) of the Public Utility Ho 30(h) of the Investme	olding Company Act	t of 1935 or Section	burden hours response	
(Print or Type Responses)					
1. Name and Address of Reporting I PIMSTONE SIMON N.	Symbol	nd Ticker or Trading ceuticals Inc. [XENE	5. Relationship of I Issuer		(s) to
(Last) (First) (N	Middle)3. Date of Earliest			all applicable)	
C/O XENON PHARMACEUTICALS INC 3650 GILMORE WAY	(Month/Day/Year) 03/11/2016 , 200 -		X Director X Officer (give t below) Presi	title 10% Ov below) ident & CEO	
(Street)	4. If Amendment, Filed(Month/Day/Ye	-	6. Individual or Joi Applicable Line) _X_ Form filed by O	ne Reporting Perso	n
BURNABY, A1 V5G 4W8			Form filed by Me Person	ore than One Repor	ting
(City) (State)	(Zip) Table I - Non	-Derivative Securities A	Acquired, Disposed of,	or Beneficially	Owned
1.Title of Security (Instr. 3)2. Transaction Date (Month/Day/Year)	2A. Deemed 3. Execution Date, if Transact any Code (Month/Day/Year) (Instr. 8)	4. Securities ionAcquired (A) or Disposed of (D)	5. Amount of 6. Securities For Beneficially (E Owned (I)	Ownership 7. 7 orm: Direct Ind D) or Indirect Be O Ov	Nature of direct
Reminder: Report on a separate line	for each class of securities ber	eficially owned directly	or indirectly.		
		Persons who res information cont required to resp	spond to the collect tained in this form a ond unless the form ntly valid OMB cont	nre not (	2 1474 (9-02)
Tabl	e II - Derivative Securities Ad (e.g., puts, calls, warran				
	action Date 3A. Deemed Day/Year) Execution Date, if	4. 5. Number f TransactionDerivative			itle and Amount of derlying Securities

## Edgar Filing: Xenon Pharmaceuticals Inc. - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	(Month/Day,	/Year)	(Instr. 3 and	4) 5
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	\$ 7.49	03/11/2016		А	50,000	<u>(1)</u>	03/10/2026	Common Shares	50,000
Repo	rting Ov	vners							
Reporting Owner Name / Address		Relationships							
	porting o wher	i unic / i uni cos	Director	10% Owner	Officer	C	Other		
PIMSTONE SIMON N. C/O XENON PHARMACEUTICALS INC 200 - 3650 GILMORE WAY BURNABY, A1 V5G 4W8		President & CEO							
Signa	tures								

/s/ Joanne Smartt,	03/11/2016
Attorney-in-fact	03/11/2010

<u>\*\*</u>Signature of Reporting Person

Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Vesting 25% on January 1, 2017, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

S (